[Justification of the choice of methodology in large scale trials of thrombolytic agents in myocardial infarction].
At first sight, the choices of methodology of the large-scale therapeutic trials of thrombolytic agents in myocardial infarction may seem surprising. They were, however, carefully reasoned with respect to the number of patients of the target population, the principal criterion, the delay before treatment, the intention to treat analysis, the duration of follow-up, etc. The reasoning behind these choices in this particular situation should even serve as a model for all phase III trials in cardiology.